Please read and agree to the terms and conditions of this site.
@xconomy.com 3 days ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com 9 days ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com 10 days ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com 10 days ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com 16 days ago
Early Bird Sale Ending for San Diego’s Xcelerating Life Sciences Conference
@xconomy.com 18 days ago
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
@xconomy.com 22 days ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com 22 days ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com 23 days ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com 24 days ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com 1 month ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com 1 month ago
Pfizer Taps Insilico Medicine to Use AI for Drug Target Discovery
@xconomy.com 1 month ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com 1 month ago
DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs
@xconomy.com 1 month ago
Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy
@xconomy.com 1 month ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com 2 months ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com 2 months ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com 2 months ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com 2 months ago
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal
@xconomy.com 2 months ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com 3 months ago
Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow
@xconomy.com 3 months ago
3 Changes We Should Make to Address the Gender Pay Gap in Medicine
@xconomy.com 3 months ago
Stryker Adds to Trauma & Extremities Biz With $4B Wright Medical Deal
@xconomy.com 3 months ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com 3 months ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com 3 months ago
Venture Investors Bets on Healthcare, and Milwaukee, With $75M Fund
@xconomy.com 4 months ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com 4 months ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com 4 months ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com 4 months ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com 4 months ago
WI Watchlist: Epic, Shine, Venture Investors, Stratatech & More
@xconomy.com 4 months ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com 4 months ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com 4 months ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com 4 months ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com 5 months ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com 5 months ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com 5 months ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com 5 months ago
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?
@xconomy.com 5 months ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com 5 months ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com 5 months ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com 5 months ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com 5 months ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com 5 months ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com 5 months ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com 6 months ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)